A meta-analysis presented at <a href="https://twitter.com/ACCinTouch&quot; target="_blank">@ACCinTouch</a> demonstrated hybrid ablation was greater than 75% effective in reducing recurrent atrial arrhythmias in patients one year out. ​

See the data: <a href="https://t.co/rYS2RaQ2PE&quot; target="_blank">https://t.co/rYS2RaQ2PE</a&gt; ​
<a href="https://twitter.com/hashtag/CardioTwitter?src=hashtag_click&quot; target="_blank">#CardioTwitter</a> <a href="https://twitter.com/hashtag/Epeeps?src=hashtag_click&quot; target="_blank">#Epeeps</a> <a href="https://twitter.com/hashtag/ACC25?src=hashtag_click&quot; target="_blank">#ACC25</a>

The cryoSPHERE® MAX delivers 60 second freeze cycles, cutting cycle time in half.​​
​
Discover the device that’s offering a faster solution to post-op pain management: <a href="https://t.co/w2w4q3MIfL&quot; target="_blank">https://t.co/w2w4q3MIfL</a&gt; ​

<a href="https://twitter.com/hashtag/cryoNB?src=hashtag_click&quot; target="_blank">#cryoNB</a> <a href="https://twitter.com/hashtag/PainManagement?src=hashtag_click&quot; target="_blank">#PainManagement</a>

Congratulations to Dr. Richard Whitlock and the <a href="https://twitter.com/HamHealthSci&quot; target="_blank">@HamHealthSci</a> team on their first case with the Isolator® Synergy™ EnCompass® Clamp. This milestone not only marks their first case but also the first case in Canada!
 
Learn more about the EnCompass Clamp: <a href="https://t.co/0lF9GfmdGb&quot; target="_blank">https://t.co/0lF9GfmdGb</a&gt;

Introducing the EPi-Ease™ Epicardial Access Device. EPi-Ease offers electrophysiologists direct and real-time visualization for a safer approach.​

Learn more about EPi-Ease: <a href="https://t.co/GkY1aVeZnt&quot; target="_blank">https://t.co/GkY1aVeZnt</a&gt; ​

<a href="https://twitter.com/hashtag/EPeeps?src=hashtag_click&quot; target="_blank">#EPeeps</a>

Compared to catheter ablation alone, significantly more patients with advanced forms of Afib* randomized to hybrid ablation &amp; LAAE remained free from atrial arrhythmias** through 3 years of follow-up.​​​

Learn more about the CEASE-AF data:​ <a href="https://t.co/sxy95CINFI&quot; target="_blank">https://t.co/sxy95CINFI</a&gt;

<a href="https://twitter.com/escardio&quot; target="_blank">@escardio</a>

At AtriCure, we’re celebrating the dedication, skill and compassion of doctors who make a difference each day.

Thank you for your commitment to improving patient lives. <a href="https://twitter.com/hashtag/DoctorsDay?src=hashtag_click&quot; target="_blank">#DoctorsDay</a>

<a href="https://twitter.com/pmcpikeville&quot; target="_blank">@pmcpikeville</a>'s Hybrid AF™ Therapy program reached 100 patients treated with <a href="https://twitter.com/hashtag/HybridAFTherapy?src=hashtag_click&quot; target="_blank">#HybridAFTherapy</a> for LSPAF. Congratulations to EPs Drs. Joseph Souza, Michael Antimisiaris, Chase Reynolds &amp; Cardiothoracic surgeon Dr. Dermot Halpin on this team approach!  <a href="https://t.co/X6V7KBXndV&quot; target="_blank">https://t.co/X6V7KBXndV</a&gt;

Designed for ultimate flexibility, cryoICE® features retractable handles and adaptable tube sets, providing excellent ergonomic support for effortless maneuverability in any hand position.​
​
Unlock the potential of cryoICE® here: <a href="https://t.co/ZMkoNoR1sd&quot; target="_blank">https://t.co/ZMkoNoR1sd</a&gt;​
​
<a href="https://twitter.com/hashtag/Cardiac?src=hashtag_click&quot; target="_blank">#Cardiac</a>

At today's Analyst and Investor Day, AtriCure leaders highlighted our leading portfolio of products and innovation pipeline, our market expansion plans and our longer-term financial goals as we continue to drive growth &amp; profitability. <a href="https://t.co/zMuphemiJw&quot; target="_blank">https://t.co/zMuphemiJw</a&gt; <a href="https://twitter.com/hashtag/InvestorDay?src=hashtag_click&quot; target="_blank">#InvestorDay</a>

Congratulations to Paul Ahlmeyer, AtriCure’s Sr. Director of Product Marketing, on winning the Culture of Excellence Award! His leadership in Cryo Nerve Block has helped provide thousands with non-opioid pain relief. Congratulations, Paul!